SLS

SELLAS Life Sciences

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 1

RSI Overbought

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About SLS

Sellas Life Sciences Group, Inc.

A late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States

Industry

Pharmaceutical

Established Date

04/03/2006

Listing Date

03/12/2008

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sellaslifesciences.com

Security Type

Common stock

Office address

7 Times Square, Suite 2503, New York, NY 10036

Business

Introduction

SELLAS Life Sciences Group, Inc., was incorporated in Delaware on April 3, 2006 as Argonaut Pharmaceuticals, Inc. In December 2017, the Company completed a business combination with a privately held Bermuda exempted company and changed its name to "SELLAS Life Sciences Group, Inc.". The company is a late-stage clinical biopharmaceutical company focused on developing new therapies for a variety of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy for nephroblastoma 1 or WT1 antigen, and GFH009, a highly selective small molecule cyclin-dependent kinase 9, or CDK 9 inhibitor. The company's lead product candidate, GPS, a cancer immunotherapy agent licensed from Memorial Sloan Kettering Cancer Center (MSK), targets the WT1 protein, which is present in 20 or more cancer types. Based on its mechanism of action as a direct immune agent, GPS has the potential to be used as monotherapy or in combination with immunotherapeutics to address a wide range of hematological, or hematological, cancer and solid tumor indications.

Company Financials

EPS

SLS has released its 2024 Q4 earnings. EPS was reported at -0.08, versus the expected -0.11, beating expectations. The chart below visualizes how SLS has performed over recent quarters, highlighting trends in earnings surprises.